

An aerial photograph of a city, likely Bellvitge, showing various buildings, roads, and green spaces. The image has a reddish-orange tint. In the top right corner, there is a white, stylized logo that appears to be a combination of letters, possibly 'IB' or 'IBI', with a heart-like shape integrated into it.

IDI BELL

BELLVITGE BIOMEDICAL RESEARCH INSTITUTE

Director's report (2020)

Gabriel Capellá, IDIBELL Director

December 23rd, 2020

Index

1. Research indicators overview
2. Budget overview
3. COVID-19 crisis
4. Organizational changes
5. Scientific Advisory Board (SAB)
6. People Management
7. Good Practices in Research
8. Management issues
9. IDIBELL Institutional activities
10. Strategic Plan follow-up



1


Research indicator's overview

Annual Report 2019

Scientific highlights

1260

Scientific articles in indexed journals



406

Indexed articles led by IDIBELL researchers



45%
182 Articles led by women




55%
224 Articles led by men

6803,237

Total Impact Factor (JCR 2018)

5,4

Average
Impact Factor
(JCR 2018)



Annual Report 2019

Activity



RESEARCH
PROJECTS

104

National

11

International

GRANTED COMPETITIVE PROJECTS

134

National

11

International



34%

Granted competitive projects
led by women



246 new clinical trials



124 active patents



195 R+D contracts



26 licences

5 active spin-offs

Internationalization indicators 2020



8,5%
(12,3%)

International
People

(International
People in IDIBELL
Payroll)



2,3M€

Granted Projects (€)



17

Granted projects
(16% success ratio)



47%

Aver. Intern.
Speakers
(External Seminars)



2

ERC projects
hosted at IDIBELL

2020 Project Highlights: European Commission



ERC Consolidator Grant
IDIBELL budget: **1.997.360 €**
PI: Carolina Florian



ERC Proof of Concept (PoC)
IDIBELL budget: **150.000€**
PI: Antonella Consiglio



MSCA-ITN-2020 (training NW)
IDIBELL budget: **501.809 €**
PI: Mariona Graupera



SC1-BHC-06-2020 (collab.)
IDIBELL budget: **87.000 €**
PI: José Luis Ferreiro

2020 Project Highlights: Other international



World Cancer Research
IDIBELL budget: **189.500€**
PI: Mariona Graupera



La Caixa Health Research
IDIBELL budget: **652.046 €**
PI: Carolina Florian



ERA-NET in Pres Medicine
IDIBELL budget: **122.836 €**
PI: Ricard Mesia

2020 Project Highlights: International - Structure



Erasmus+

Enriching lives, opening minds.

Investigating As Researchers at
School is a GAME (STARS GAME)
Pressupost IDIBELL: **93.529 €**

Horizon 2020

Science
with and for Society

SWAFS. Paths to Successful
Innovations (ISPAS)
Pressupost IDIBELL: **22.962 €**

2020 Project Highlights: National Calls



FEDER projectes singulars inst.
d'infraestructures d'R+D
Pressupost IDIBELL: **1.062.000 €**



Ajudes a plataformes de suport:

- Biobanc: **334.950 €**
- Innovació: **298.650 €**
- Assajos clínics: **412.500 €**



**Projecte d'especialització i
competitivitat territorial PECT
(RIS3CAT i FEDER)**

Total Budget: 3.135.512,12€
IDIBELL Budget: **1.923.221 €**
(with 50% cofinancing)

2020 Project Highlights: National calls



**RETOS / Generación conocimiento
/ Jovenes Investigadores (JIN)**



AECC Innova 2020 (New)

Total IDIBELL : **1.269.048 €**

PIs: Casanovas, Capellá, Muñoz-Pinedo,
Plass, Queralt i Vaquero (JIN)

6 projectes concedits dels 9 demanats

Aptamer-mediated delivery of siRNAs

IDIBELL budget: **179.842 €**

PI: Oscar Martínez-Tirado

D'un total de 3 projectes concedits

2020 Project Highlights: National calls



AES 2020 (provisional resolution)

Projectes	2.801.404 €
21 projectes concedits	2.785.904 €
1 projecte DTS concedit	15.500 €
Ajuts RRHH	1.733.459 €
3 contractes intensificació	90.000 €
2 contractes Miguel Servet I	485.000 €
2 contractes Miguel Servet II	202.500 €
5 contractes Río Hortega	268.660 €
3 contracte Sara Borrell	241.794 €
4 contractes PFIS	412.000 €
2 Ajuts de mobilitat M-AES	33.505 €
TOTAL AES 2020:	4.534.863 €

La Marató



Malalties minoritàries

Convocatòria 2020

7 projects coordinated



Narváez, Pineda, Rivera,
Pujana, Nunes, Torras i
Casasnovas; Ventura (UB)

3 projects in collaboration

Consiglio, Giorgetti i Padró

TOTAL La Marató 1.588.926 €

Innovation indicators overview



Spin-offs at IDIBELL



Development of customizable stents (Mitjançant 3D technology) and bioactive coatings (antibacterial and / or drug release).

Founding year: 2016



Development and commercialization of a new Kit for the early detection of Alzheimer's by means of an epigenetic analysis in blood, from measurements of methylcytosines in the mitochondrial DNA.

Founding year: 2017



Preclinical services including Orthoxenograts® generation and access to OrthoXenoBank®. It also offers personalized treatment services to select the best cancer treatments.

Founding year: 2014



Development of a new molecule to prevent ultra-resistant gram-negative nosocomial infections in Intensive Care Units (ICUs).

Founding year: 2018

New Spin Off Aptadel, SL



Tecnology

Aptadel: Multifunctional RNA molecules (chimera: aptamer+siRNA) to treat Ewing's Sarcoma and other sarcomas with high levels of EphA2 receptor.



Team

- **Dr. Oscar Martínez Tirado:** Principal Investigator
Chairman of the Board of Directors
- **Alba Foundation** (Venture Phil.): Rafa Perez
Member of the Board of Directors
- Interim **CEO + CSO**



IP

Patent: EP19382451.3

Ownership: IDIBELL, University of Iowa & Alba Foundation

Spin-Offs projects

AngioTheraGnostics (ATG)



AngioTheraGnostics: Development of a new drug to prevent antiangiogenic resistance accompanied by a diagnostic kit with a specific biomarker for the selection of those patients who will benefit from treatment.



Dr. Gabriela Jiménez: Project Manager (IDIBELL)
Dr. Oriol Casanovas: Principal Investigator (ICO-IDIBELL)
Dr. Ramon Salazar: Clinical oncologist (ICO-IDIBELL)

Purpose Tx



Purpose Tx: New anti-inflammatory biomolecule that acts selectively on inflammatory precursors and promotes tolerance for the treatment of autoimmune diseases: lupus nephritis, inflammatory bowel disease (IBD) and rheumatoid arthritis. The main indication would be IBD.




Dr. Josep Maria Aran: Principal Investigator (IDIBELL)
Dr. Anna Luque: Researcher (IDIBELL)
Dr. Jordi Guardiola: Clinical digestologist (HUB-IDIBELL)

2

Budget overview

- Evolution of funds raised
- Annual closings


Evolution of funds: Annual budget



27 26,7 27,1 26,9 28,8 28,2 27,8 28,1 *# Total Annual budget

* estimated; # after CMRB integration

Raised funds 2016-2020: competitive calls and innovation



Annual closings

	2016	2017	2018	2019	2020 estimated
a. INCOME	26.919.189,46	28.815.427,01	28.222.209,52	28.810.833,70	28.132.380,27
b. EXPENSES	-26.868.178,78	-28.668.951,34	-28.266.848,71	-28.910.109,70	-28.171.224,88
TOTAL	51.010,68	146.475,67	-44.639,19	-99.276,00	-38.844,61
VAT regularization	0,00	-476.704,34	-236.836,63	-50.630,80	0,00
PROFIT/LOSS	51.010,68	-330.228,67	-281.475,82	-149.906,80	-38.844,61

3



COVID-19 crisis

Pandemic management at IDIBELL



Crisis Committee

11 members
Regular meetings



Crisis and lock-down easing protocols

7 versions
Catalan and English



Covid19 Mailbox

25 announcements
2.500 mails received



Company certificates

Adapted to each phase
875 elaborated

Pandemic management: Onsite work



PERSONAL PROTECTIVE EQUIPMENT (PPE)

Circulation and offices

To access and move around the facility and when working with more people, all personnel needs to wear a surgical mask.


Non-COVID research¹⁹

Usual instructions (lab coat, glasses and gloves) and surgical mask, in addition to the specifications of each room.

COVID19 research

Biosecurity level 2 spaces, FFP2 mask, waterproof and autoclavable coats, glasses, double gloves, cap & shoe covers.

Pandemic management: Prevention



467

Procedures processed

39

Vulnerabilities assessed

113

Covid-19 assessed

124

PCR performed (29 positives)

42

Preventive isolations/PCR+

249

Seroprevalence analysis

9

Support psychological

488

Consultations attended

125

People trained

236

Capacities calculated

71

Visits / trips coordinated

8

Protocols in collaboration

Project Highlights: COVID-19 calls

/Salut

3 projects from DGRIS: **614.505 €**
Drs J. Carratalà, X. Solanich i R. Máñez
Total: 19 projects from 42 applications




3 projects from ISCIII: **515.256 €**
Drs J. Carratalà, O. Bestard i J. Bas
Total: 129 projects from +1500 applications



ENVISION: Artificial intelligence & COVID-19 at ICUs
Drs R. Mañez i M.J. Colomina
IDIBELL budget: **115.000 €**

COVID-19 Projects



+80

During the April-November period, more than 80 studies were carried out between basic research projects, clinical trials and observational studies.

+25

Clinical Trials

+25

Research Projects

Including collaborations with Mount Sinai Hospital or the Consortium "COVID Human Genetic Effort", among others

COVID-19 Research: Results

41 Collaborative
research papers

27 Lead research
papers

2 Fundraising
campaigns

95k Euros received

Science

THE LANCET
Haematology

 **CellPress**

THE LANCET
Public Health



4

Organizational changes


- Organizational chart
- Research organization
- CRM[B] Merging

Organization chart

People and Strategy Directorate becomes the **Organization and People Directorate**.

Within this area, the **People Department** is created encompassing the Talent, People Management and Occupational Health Units.


Communications Unit and Fundraising Units merge and report directly to the General Directorate.



Organization chart


Regenerative Medicine Area is already on the institutional web and the rest of corporative materials.


The CMRB's scientific services are integrated into IDIBELL's research support units or new ones are created.



Research organization

2019
-
2022





CANCER



RAMON SALAZAR

(1) Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell)



ISABEL FABREGAT



ESTEVE FERNANDEZ

(2) Epidemiology, Public Health, Cancer Prevention and Palliative Care



REGENE. MEDICINE


(4) Regenerative Medicine



ANGEL RAYA



FRANCISCO CIRUELA



NEURO

(3) Neuroscience

EDUARD MONTANYA
(5) Diabetes and Metabolism Program



VIRGINIA NUNES
(6) Genes, Disease and Therapy



ANGEL CEQUIER

(7) Cardiovascular, Respiratory and Systemic Diseases and cellular aging



JOSEP M. LLOP

(8) Digestive system, diagnostics, pharmacogenetics, care support and clinical prevention



TRANSL. MEDICINE



JORDI CARRATALÁ

(9) Infectious disease and transplantation Program

Calls for Program Coordinators 19-20

ONCOBELL



ONCOBELL – Appointment of R Salazar & I Fabregat co-coordinators (clinic&basic team). JM Piulats to take over R Salazar position

NEUROBELL



NEUROBELL – Appointment of F Ciruela

EPIBELL



EPIBELL– Appointment of E. Fernández

Changes in group leaders 19-20



Cardiovascular Diseases

Dr Josep Comín
(previous Dr Cequier)



Cellular and Molecular Neurobiology

Dr Artur Llobet
(previous Dr Solsona)



New IDIBELL Group at ONCOBELL Vascular-related diseases group

Group leader Dr Mariona Graupera
(former PI Dr Casanovas)



Hereditary Cancer

Dr Conxi Lazaro new co-group leader
with Dr Capellá



Nephrology and renal transplantation

Dr Oriol Bestard new co-group leader
with Dr JM Cruzado

CMR[B] integration

[INTRAMURAL]

Regenerative Medicine Area
Regenerative Medicine Program



**IDI
BELL**

Regenerative Medicine
program

idibell.cat

@idibell



[EXTRAMURAL]

Program for Translation of Clinical
Regenerative Medicine of Catalonia

P-CMR[C]

p-cmrc.cat

@p_cmrc



Regenerative Medicine Program



Program COORDINATOR

Angel Raya

Stem Cell Potency Research group

Angel Raya's Lab



Pluripotent Stem Cell Therapy Research group

Anna Veiga's Lab



Gene Regulation of Cell Identity Research group

Mireya Plass' Lab



Hematopoietic Stem Cell Biology and Leukemogenesis

Alessandra Giorgetti's Lab



Stem Cell Aging Research group

Carolina Florian's Lab



Cellular plasticity and regeneration Research group

Jordi Guiu's Lab



Pancreas Regeneration

Meritxell Rovira's Lab

P-CMR[C] organization

P-CMR[C]



P-CMR[C] DIRECTOR

Angel Raya



P-CMR[C] Co-Clinical DIRECTOR

Antoni Bayés



STEM CELL BANK

Anna Veiga

Promoted by



**IDI
BELL**

Institut d'Investigació
Biomèdica de Bellvitge



Generalitat de Catalunya
**Departament
de Salut**

P-CMR[C] ADVISORY BODY

- Representatives of the Catalan IIS
- Representatives of the Health Department from the Generalitat de Catalunya

(to guide the implementation of the P-CMR[C])

5

Scientific Advisory Board (SAB)

IDIBELL SAB



Ana Maria Cuervo MD, PhD

Professor of Department of Developmental & Molecular Biology
Albert Einstein College of Medicine



Ernest Arenas MD, PhD

Professor of Stem Cell Neurobiology
Chairman of the Department of Medical Biochemistry and Biophysics
Karolinska Institute



Paolo Gasparini MD, PhD

Professor of Istituto di Ricovero e Cura a Carattere Scientifico maternoinfantile Burlo Garofolo



Ana Aranda PhD

Professor of CSIC
Departamento de Fisiopatología Endocrina y del Sistema Nervioso
Inst. de investigaciones Biomédicas “Albert Sols”



Sonia Martínez PhD

Ex-Directora General de Innovación en Conselleria de Sanidad de la Xunta de Galicia



Lisardo Boscá PhD

Professor of CSIC
Centro de Investigaciones Biomédicas Alberto Sols de Madrid



Robert Sackstein MD, PhD

Dean of the Herbert Wertheim College of Medicine at the Florida International University (FIU). Senior Vice-President of the FIU Academic Health Center

Research group evaluation: Timeline

19 groups

2017-2018

1 Research Program

- Oncobell Program (19 groups)

26 groups

2018-2019

4 Research Programs

- Neurobell (9 groups)
- Epibell (4 groups)
- PEBC (9 groups)
- Genes, Disease & Therapy (4 groups)

21 groups

2019-2020

4 Research Programs

- Diabetes & metabolism (3 groups)
- Cardiovascular, Respiratory, Systemic Diseases & cellular aging (4 groups)
- Digestive system, diagnostics, pharmacogenetics, care support and clinical prevention (9 groups)
- Infectious disease and transplantation (5 groups)

6

People Management

- HRS4R renovation in March 2021
- Active Tenure Tracks
- Professional career for researcher's implementation
- Training: Areté Program

HRS4R Action Plan (evaluation March 21')



Conclusions from the 2019 Survey

02. Recruitment and selection



- Poor knowledge and suitability of the evaluation and appraisal system
- Lack of programs and initiatives to foster mobility

04. Career development & training



- Poor knowledge of the training plan and low level of training satisfaction

03. Working conditions



- Poor knowledge of the professional career structure
- The current work environment does not allow professional growth
- Poor representation on consultation and decision-making bodies
- Overall salary dissatisfaction
- Poor knowledge of the suggestions and appeals procedures and their suitability
- Poor communication between decision-making bodies and staff

Current Tenure-track



CANCER

REGENERATIVE
MEDICINE



NEUROSCIENCE



TRASLATIONAL
MEDICINE

TENURED DURING THE PERIOD

Tenured in 2020



CARLES
SORIANO



XAVIER
ALTAFAJ**



STEPHANE
FOURCADE



ALESSANDRA
GIORGETTI



**Left IDIBELL in summer 2020

ACTIVE TENURE-TRACK



ESTELA
CÁMARA



ÁLVARO
AYTÉS



RAÚL
ZAMORA



DAVID
LLOBET



RUTH
RODRIGUEZ



MERITXELL
ROVIRA



CAROLINA
FLORIAN



MIREYA
PLASS



JOAN JOSE
ROJAS



JORDI
GUIU



JORDI
BONAVENTURA



*To be evaluated
in 2021*

*To be evaluated
2022*

*To be evaluated in
2024*

*To be evaluated
in 2025*

To be evaluated in 2026

Professional careers for researchers

96% of payroll PIs inside the professional career plan of IDIBELL

R3A

Julian Cerón

Ana Maria Sola

Núria Lloberas

Oscar Martínez-Tirado

Cristina Muñoz-Pinedo

Purificación Muñoz

Sara Larriba

R3B

Laura Valle

Mariona Graupera

R4

Josep Maria Aran

Eric Duell

Virginia Nunes (UB-Professor)

Àngel Raya (ICREA Researcher)

Aurora Pujol (ICREA Researcher)

R4-E Emeritus

George Thomas

Sara Kozma

Anna Veiga

Mercè Pérez

Isabel Fabregat

Àngels Fabra

Areté website



100% online

Learn at your own pace



Retorn a l'IDIBELL: Protocol de desconfinament en 4 etapes



CONTINUE COURSE

424 students



Recomendaciones de ergonomía para tu oficina en casa



CONTINUE COURSE

70 students

NEW: Dirige a tu equipo a distancia

11 June 2020 12:00 - 14:00



-  **Live webinar**
Scheduled activity
-  **2 h of training**
-  **Beginner level**
-  **Spanish**

NEW: Microsoft Teams

17 June 2020 12:00 - 13:30



-  **Live webinar**
Scheduled activity
-  **1 h 30 min of training**
-  **Beginner level**
-  **Spanish**

#IDIBELLconnect Webinars



Internal communication channels & brand
Microsoft Yammer &
IDIBELL Seminars weekly newsletter



 **7** videos

13 speakers

IDIBELL Seminars Academic Year 2019 – 2020
(before March 2020)

5 speakers

3 speakers

4 speakers

2 speakers



85 participants

12 panelists


Panel I: Opportunities and benefits of an academic career

Panel II: What you should know about jobs in the pharma and biotech industry

Panel III: What alt-careers are out there for me with a PhD?

2 Keynotes: Breaking the silos | Intellectual Property in life sciences

1 Workshop: Writing an effective CV and cover letter



175 participants



4 SHORT TALKS

11 POSTERS



3 SHORT TALKS

16 POSTERS



3 SHORT TALKS

8 POSTERS



1 SHORT TALK

7

Good Practices in Research

- Ombudsperson renewal & CIR committee
- Good Practices Research Guide Update
- Laboratory notebooks policy
- Animal facility accreditation

Ombudsperson renewal



Dr. Xavier Bosch IDIBELL (2015-2020)

Two major issues during 2015-2018 period:

- **Conflictive relationship between with tenure-track researcher and group leader**
- **Assessment of putative scientific fraud**



Dr. Anna Veiga IDIBELL (June 2020-)

- Member of the Regenerative Medicine CEIC
- Director of the BCN Cell Lines Bank
- UB and UPF Professor
- Grifols S.A. Advisor (2008-2019)

Research Integrity Committee (CIR)

- **PRESIDENT = Anna Veiga**, Director Barcelona Stem Cell Bank, IDIBELL Researcher, Ombudsperson
- **Francesc Xavier Bosch**, Cancer Epidemiology Res. Program ICO, IDIBELL Researcher and former Ombudsperson
- **Josep Maria Cruzado**, Head of the Nephrology Department, IDIBELL Researcher and UB Professor
- **Rafael Máñez**, Head of Intensive Internal Medicine Department, IDIBELL Researcher
- **Jordi Trelis**, Director of Care, Clinical Director of Palliative Care ICO
- **Ernest Nadal**, Medical Oncology Department ICO, IDIBELL Researcher
- **Isabel Fabregat**, ONCOBELL Program Coordinator, IDIBELL Researcher and UB Professor
- **Concepció Soler** IDIBELL Researcher and UB Professor
- **Itziar de Lecuona**, Deputy Director of the Bioethics and Law Observatory at the University of Barcelona, Member of the UNESCO Chair in Bioethics, UB Professor
- **Enric Sospedra**, Secretari CEIm Bellvitge - HUB, Professor UB

Update of Good practices guide

Adaptation to the **CERCA code (Novembre 2018)**

INDEX (main updates)

- Research and biomedical research principles
- Research project design (Incorporation **Data Management Plan** and **Impact Assessment Plan**)
- Research with HUMANS (Obtaining **biological samples**, availability and conservation. **Biobanking**)
- Research with ANIMALS
- Security, health and environment
- Communication and Divulgarion of results (**CERCA** acknowledgment and **IDIBELL affiliation regulations; Open Access** – UB Digital repository)
- Ombudsperson and **Research Integrity Committee**
- **Conflict of interest** (Procedure for the declaration of Col)
- **Research misconduct** (Procedure for suspected misconduct)

Laboratory notebooks policy

GOOD PRACTICE IN RESEARCH – CERCA CODE OF CONDUCT NOVEMBER 2018



The notebooks or documents are owned by the CERCA center where the work has been carried out.

IDIBELL LABORATORY NOTEBOOK



Free to all IDIBELL affiliates

ACCURATE RECORD KEEPING

- Preliminary record used to establish ownership of an invention and dates of discovery
- Experiments can be repeated and the results replicated and confirmed
- Repository of all primary data and results

Animal Facility



The CEEA to evaluate the experimental procedures and detect and solve incidences. Report to be taken into consideration by the Directorate.



PECT-financed animal facility renewal has just finished. Entering in the final phase encompassing validation, cleaning and preparation for the future reopening



Reopening scheduled for February 2021

8

Management issues

- Digital transformation
- Data management

Digital transformation:

Disposal of paper warehouses

Destruction of current documents
Data Protection
Freeing up space

Digital signature

Official documentation: IDCat
Unofficial documentation: unqualified signature

Documentation classification

Circuits / traceability
Availability - Document Manager
Systems audit
ERP bidding

Teleworking

Law enforcement: Who, tools and resources needed
New distribution of spaces
Work by objectives and evaluation of compliance

IDIBELL Data (Route map)



- user@idibell.cat
- 1TB
- Private use of data
- No data specifications is needed



- Dades sensible


ELECTRONIC NOTEBOOKS




- FAIR Principles
- Metadata form is mandatory
- Private use (PI)
- Easy access (PI)
- Unlimited and free space for 2-3 y
- Allow data sharing with external researchers
- Security System guarantee (ISO)

Services offered:


- Data Management Plan (DMP)
- Data anonymization
- Data curation
- Sharing data with third parties &/or open repositories



- Data from IDIBELL Archive > 2-3y
- Private use
- Limited access
- Storage guarantee for 7-8 y
- Security system



- FAIR Principles
- Data from IDIBELL Archive > 2-3y
- Data form publications
- Open Access data



9

IDIBELL Institutional activities

- SINERGIA 2020
- Salvem Vides '20

Sinergia 2020 (Virtual open house)

sinergia.l-h.cat



New website & image

Digitization of the experience
Audiovisual repository
Thematic navigation

First 3 weeks

+4.000 website visits
+11.000 pages viewed
+3.500 video views
+500h of video watched
+300k social media reach

+ 11 live talks in streaming (28N)

“We save lives”

- First **global fundraising campaign** at IDIBELL
- Strategic objectives:




VISIBILITY
IDIBELL brand
Research programs



FUNDRAISING
Crowdfunding
Sponsors & philanthropy



AWARENESS
Research support
Sense of belonging



2019: Oncobell program

→ cancer research

- Personalized medicine
- Immunotherapy
- Support to young talented researchers



2020: Neurobell program

→ Neuroscience research

- Cognitive impairment
- Neurodegenerative diseases

SUSPENDED BECOUSE OF THE COVID-19

10

Strategic Plan Follow-up

European reference in health sciences & Innovation



1 Encourage **internal synergies** and **external alliances**

2 New Research Area on **Regenerative Medicine** P-CMR[C]

3 Joint actions with hospitals to promote **clinical research**

4 **Personalized Medicine Strategy**

5 **Internationalization**

6 Foster **innovation** to improve our impact on citizens' health

Bellvitge Campus as a reality



8 Improve research **visibility**

9 Build the **IDIBELL community**

7 Deployment of a **Health Micro-Cluster**

10 **Responsible Research & Innovation Strategy**

Talent in health sciences



11 Comprehensive model for **IDIBELL people management**

12 Attract talented **junior researchers**

13 Attract and retain **senior researchers**

Sustainable growth



14 Ensure an **efficient & transparent** researcher-oriented organization

15 An **enabling environment** for research (support)

16 Increase **funding** sources

FOLLOW-UP IDIBELL STRATEGIC PLAN

QUICK WINS 2020

1T
2020

- SL1 Adscription procedure for local partners (CSI, IMLCFC)
- SL10 CIR nomination, Procedure for declaration of Col, and GRP review
- SL11 Define and deploy the Model of Professional Development (MPD) for Scientific Support (SS) and Management Support (MS): IDIBELL Evolve

3T
2020

- SL5 Organization of Oncobell & Neurobell Symposia
- SL7 Financial support for Health Micro-Cluster (Fons Singulares; PECT II pending)
- SL9 Deploy the new intranet
- SL10 Organize Co-creation activities within Patient associations and research groups
- SL13 Define the strategy for intensifications & compensation model for non-IDIBELL payroll: IDIBELL EVOLVE
- SL14 Perform an adscription campaign "IDIBELL reload" (IDIBELL anual Retreat)

Postponed due to Covid
Not Accomplished
Pending
Accomplished

2T
2020

- SL1 Internal Call for Multidisciplinary Research Projects
- SL4 Research Data Management: Data Protection Officer (hired), IDIBELL DMP guidelines, Laboratory notebooks, DM policy (pending)
- SL8 Deploy the IDIBELL website
- SL9 Welcome procedure & Staff Handbook
- SL15 Define a policy for lab and office space use and distribution and direct support to groups
- SL16 2nd IDIBELL fundraising campaign (Neurobell)

4T
2020

- SL2 Deployment of Regenerative Medicine: New recruitments, Website, EoI & Benchmarking
- SL3 Optimization of Trial's management: Process review, UICEC's ISO9001
- SL4 Launching the PerMed and Adult Rare Disease Research Program
- SL5 Increase the success ratio in International Grants
- SL6 Review IDIBELL Intellectual Property Regulations; Inauguration of the Industry Advisory Committee
- SL8 ≥ 70 % of publications signed as IDIBELL
- SL12 Define and implement a (MD) PhD training program
- SL14 Complete Evaluation of all the research groups at IDIBELL



Bones

(i seques)

Festes


**IDI
BELL**





Thanks!



[@IDIBELL_cat](https://twitter.com/IDIBELL_cat)



director@idibell.cat

Idibell.cat